[Prophylaxis of pertussis: development and use of acellular pertussis vaccine].
Modern data substantiating the expediency of the use of acellular pertussis vaccine were analyzed. Serious postvaccinal complications caused by the action of the corpuscular pertussis component of adsorbed DPT vaccine served as the basis for the development of acellular pertussis vaccine (APV). During the period of 1990-1996 as many as 8 international field trials of the effectiveness of APV were carried out. The results of these trials and studies were evaluated in accordance with the unified programs and criteria. The vaccines under test differed by the composition of Bordetella pertussis purified antigens they contained, the methods of their purification and the detoxification of pertussis toxin. All tested APV, with the exception SKB-2, possessed pronounced prophylactic activity.
R P
RP
Chuprinina
I A
IA
Alekseeva
N A
NA
Ozeretskovskiĭ
D001886:Bordetella pertussis / Q000276:immunology*; D002986:Clinical Trials as Topic; D006801:Humans; D010567:Pertussis Vaccine / Q000008:administration & dosage*; D016896:Treatment Outcome; D014611:Vaccination; D022282:Vaccines, Acellular / Q000008:administration & dosage; D014917:Whooping Cough / Q000517:prevention & control*
D010567:Pertussis Vaccine; D022282:Vaccines, Acellular